Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin.
10.4048/jbc.2015.18.4.400
- Author:
Suee LEE
1
;
Sung Yong OH
;
Sung Hyun KIM
;
Ji Hyun LEE
;
Dae Cheul KIM
;
Se Heon CHO
;
Miri LEE
;
Hyo Jin KIM
Author Information
1. Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea. kimhj@dau.ac.kr
- Publication Type:Case Report
- Keywords:
Breast;
Eribulin;
Malignant adenomyoepithelioma;
Neplasm metastasis
- MeSH:
Abdominal Wall;
Adenomyoepithelioma*;
Breast*;
Diagnosis;
Drug Therapy;
Female;
Humans;
Mastectomy, Modified Radical;
Middle Aged;
Neoplasm Metastasis;
Phenobarbital;
Superior Vena Cava Syndrome;
Taxoids
- From:Journal of Breast Cancer
2015;18(4):400-403
- CountryRepublic of Korea
- Language:English
-
Abstract:
Adenomyoepithelioma (AME) of the breast is an uncommon tumor characterized by its dual differentiation into luminal cells and myoepithelial cells. In most cases these tumors have a benign clinical course, but distant metastases have been reported. We present the case of a 51-year-old woman diagnosed with malignant AME. The patient underwent a right modified radical mastectomy, and pathological examination confirmed the diagnosis of malignant AME. Ten months after the operation, multiple hepatic, pleural, and abdominal wall metastases were detected. A number of palliative chemotherapeutic agents were tried, including anthracycline and taxanes. However, the disease continued to progress, and superior vena cava syndrome developed as a result of direct tumor invasion. The patient received salvage eribulin monotherapy. After two cycles of this treatment, her clinical symptoms were ameliorated, and a computed tomography scan showed a partial response. Eribulin chemotherapy was thus effective in treating malignant AME in this case.
